SOUTH SAN FRANCISCO, CA, TRex Bio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, announced the close of an oversubscribed $84 million Series B financing round. The financing was led by Delos Capital.
TRex Bio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, announced the close of an oversubscribed $84 million Series B financing round. The financing was led by Delos Capital, with additional new investors Avego BioScience Capital and Agent Capital. Existing investors Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation - JJDC, Inc.), Alexandria Venture Investments, and Polaris Partners also participated.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
